Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Mangano DT, Layug EL, Wallace A, Tateo I
Nutritional support focusing on anti-inflammatory eating patterns
The next frontier in GLP-1 drug development GLP-1 medications have already reshaped obesity management, but research pipelines suggest that what we have today is just the beginning
The Role of Semaglutide in Type 2 Diabetes Management and Weight Management Initially, semaglutide was approved by the Food and Drug Administration (FDA) in 2017 under the brand name Ozempic for the treatment of type 2 diabetes
Safety signals identified through extended follow-up include: Gastrointestinal effects : Nausea, vomiting, and diarrhea remain the most common adverse events, typically diminishing over time but causing discontinuation in approximately 57% of patients Gallbladder disease : Increased incidence of cholelithiasis and cholecystitis, possibly associated with weight loss, though the exact mechanism remains under investigation Diabetic retinopathy : Risk of complications, particularly with rapid glycemic improvement in patients with pre-existing retinopathy Acute kidney injury : Risk associated with severe gastrointestinal adverse events leading to dehydration Pancreatitis : Rare cases reported, though causality remains uncertain
US$ 28.56
US$ 20.91
US$ 27.20
US$ 21.76
US$ 29.96
US$ 20.74
US$ 27.80
